Sharemaestro Newsreel

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts

Kyverna Therapeutics (NASDAQ:KYTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $30.00, significantly above its current price of $8.08. Insider ownership has increased, with hedge funds and institutions owning 18.08% of the stock. The company recently …

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages

Palisade Bio, Inc. (NASDAQ:PALI) has received a consensus "Buy" recommendation from brokerages, with an average one-year target price of $9.00. The article details recent analyst ratings, including several "buy" and "strong-buy" recommendations, alongside some changes to "hold" and "sell" ratings. It also highlights recent …

AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85%

Hyperion DeFi (HYPD) Q2 2026 Earnings Call: Adjusted Gross Profit Rises 20%

Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System

The California State Teachers Retirement System significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 2,158.3% in the first quarter, now holding 105,101 shares. Several other institutional investors also adjusted their positions in the company. Despite missing earnings per share estimates, Eyepoint Pharmaceuticals exceeded …

Stock index futures largely flat after S&P 500 closes at record high

[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) …

Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX

Assenagon Asset Management S.A. significantly reduced its stake in REGENXBIO Inc. by 82.7% in the second quarter, now holding 169,279 shares valued at $2.03 million. Despite this, institutional investors still own a substantial 88.08% of the company. REGENXBIO recently surpassed analyst estimates for quarterly …

Cibus (CBUS) Q2 2026 Earnings Call: Rice Launch Moves to 2028 as Costs Decline

Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA

Bank of America Corp DE increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 6.6% in the first quarter, now owning 1,619,994 shares valued at approximately $37.75 million. Institutional investors and hedge funds collectively own 99.12% of Innoviva, and the stock currently has an average …

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate …

Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson

Janus Henderson Group Ltd. filed an amended beneficial ownership report (SCHEDULE 13G/A) for Dyne Therapeutics Inc. (DYN), indicating that its affiliated asset managers beneficially own 11,997,738 shares, representing 7.3% of the class as of June 30, 2026. These shares are held in client Managed …

Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE

Dimensional Fund Advisors LP has reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 38.3%, selling 29,593 shares but retaining 47,697 shares valued at $2.4 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $111.69, while institutional investors collectively …

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past …

Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Dimensional Fund Advisors LP reduced its stake in Rhythm Pharmaceuticals, Inc. by 40.2% in the first quarter, selling 12,867 shares and retaining 19,151 shares valued at approximately $1.67 million. Despite the sale, Rhythm Pharmaceuticals reported strong quarterly revenue growth of 46.9% year-over-year and beat …

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

Assenagon Asset Management S.A. Increases Stake in Fortrea Holdings Inc. $FTRE

Assenagon Asset Management S.A. significantly increased its stake in Fortrea Holdings Inc. by 90.7% in Q2 2026, now owning 173,129 shares valued at $3.0 million. This comes as Fortrea reported strong quarterly results, beating EPS and revenue estimates, while analysts maintain a "Hold" rating …

ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370

This article provides a detailed overview of ADMA Biologics Inc. (ADMA) stock, including its current price, market performance, key financial figures, and analyst ratings. It also offers technical analysis, company profile, ownership breakdown, and related instruments in the pharmaceutical sector.

Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX

Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS

Dimensional Fund Advisors LP significantly increased its stake in Aclaris Therapeutics, Inc. by 88.8% in the first quarter, now holding 511,461 shares valued at approximately $1.91 million. This move is part of a broader trend of institutional investment, with such entities owning 98.34% of …

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

Dimensional Fund Advisors LP significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 133.9% in the first quarter, now holding over 531,000 shares valued at $2.77 million. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 38.13% …

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics reported Q2 2026 earnings, highlighting its transition to a commercial-stage company following the successful launch of AVLAYAH, a new therapy for Hunter syndrome. The company achieved $3.6 million in net product revenue in its first full commercial quarter and provided Q3 guidance …

Why SELLAS (SLS) Posted a Wider Net Loss but a Narrower Per-Share Loss This Quarter

SELLAS Life Sciences Group (SLS) reported a wider net loss in Q2 2026 but a narrower loss per share, driven by increasing expenses related to late-stage oncology programs. The company's investment narrative continues to revolve around the success of its Phase 3 REGAL trial …

Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Rezolute, Inc. (NASDAQ:RZLT) by 273.7% in the first quarter, now owning 530,229 shares valued at $1.62 million. Institutional investors collectively hold 82.97% of the company, which is a clinical-stage biopharmaceutical firm focusing on therapies for …

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrower losses in Q2 2026 and appointed an AI-focused investor to its board, signaling a push into advanced computation for R&D. Despite this, the company still faces significant financing risk due to ongoing heavy losses and a short cash runway, with …

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside

Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.

Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse …

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed

Zenas BioPharma (ZBIO) reported significantly wider losses in Q2 2026, with a net loss of US$111,460,000, despite US$1,000,000 in revenue. These financial results, coupled with leadership changes like the CFO transitioning to a Strategic Advisor role and a new board appointment, are sharpening the …

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park

Tempest Therapeutics has secured an equity facility of up to $50 million from Lincoln Park Capital Fund, LLC. This agreement provides Tempest with a flexible capital source for operations and clinical development, allowing the company to control the timing and amount of share sales. …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC

Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 30% in the second quarter, selling 358,669 shares and retaining 835,204 shares valued at $3.06 million. The company's shares opened at $3.71, near its 12-month low, and it reported a quarterly loss …

Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Omeros Corporation (NASDAQ:OMER) by 85.2% in the first quarter, now holding 179,594 shares valued at $1.9 million. This comes as Omeros recently reported strong Q2 earnings, beating analyst expectations with $0.02 EPS and $28.53 million …

Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI

Dimensional Fund Advisors LP significantly reduced its stake in OmniAb, Inc. by 18.9% in the first quarter, although it still holds 1.75 million shares valued at $2.74 million. OmniAb exceeded analyst expectations with its recent earnings report, posting a smaller-than-expected loss and higher revenue, …

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …

Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target

MediWound Ltd. (MDWD) reported Q2 2026 revenue of $3.09–3.10M, with a net loss of $7.39M and shares down 5.4% for the quarter. The company stated that its therapy, EscharEx, is targeting a $4 billion U.S. non-surgical tissue repair market, which it identifies as its …